



Vestibular and auditory manifestations of migraine

Tania Benjamin^a, Danielle Gillard^a, Mehdi Abouzari^b, Hamid R. Djalilian^{b,c}, and Jeffrey D. Sharon^a

Purpose of review

The purpose of this narrative review is to discuss current literature about vestibular migraine and other cochleovestibular symptoms related to migraine.

Recent findings

Vestibular migraine affects 2.7% of the US population. Misdiagnosis is common. The pathophysiology is currently unknown but new research shows that calcitonin gene-related peptide, which is implicated in migraine headaches, is expressed in the audiovestibular periphery. A recent large-scale placebo-controlled trial looking at metoprolol for vestibular migraine was terminated early due to poor recruitment; however, at study completion, no differences were seen between treatment arms. Many other audiovestibular symptoms have been shown to be associated with migraine, including tinnitus, hearing loss, aural fullness, otalgia, and sinus symptoms. Migraine is also associated with risk for developing numerous otologic conditions, including Meniere's disease, vestibular loss, Benign Paroxysmal Positional Vertigo, and sudden sensorineural hearing loss. There is now some evidence that patients may experience fluctuating hearing loss and aural fullness without vertigo in association with migraine, which is called cochlear migraine.

Summary

Migraine can cause a variety of audiologic and vestibular symptoms, and further research is required to understand how migraine affects the inner ear.

Keywords

audiovestibular symptoms, headache, vertigo, vestibular migraine

INTRODUCTION

Vestibular migraine is a distinct variant of migraine that causes vestibular symptoms, with or without an accompanying migrainous headache. Patients frequently also experience phonophobia, photophobia, head pressure, and motion sensitivity. Aural symptoms, including tinnitus and aural pressure, are common as well. Furthermore, there's emerging evidence that hearing loss may be associated with migraine, without vestibular symptoms, and this has been termed cochlear migraine [1,2]. Migraine is a common culprit for many otolaryngologic symptoms, including sinus pressure, facial pain, and facial numbness. Finally, migraine is statistically associated with several other vestibulopathies, including benign paroxysmal positional vertigo, bilateral vestibular loss, Meniere's disease, and benign paroxysmal vertigo in childhood and adulthood [3–8]. In this manuscript, we will review how migraine causes auditory and vestibular symptoms, focusing on recent developments with vestibular migraine.

VESTIBULAR MIGRAINE

Epidemiology

The overall prevalence of vestibular migraine in the USA is estimated to be 2.7%, and it may be the most common cause of episodic vertigo in adults [9,10]. Underdiagnosis appears to be common. In a study assessing vestibular migraine prevalence, two thirds of patients with vestibular migrainewere evaluated

^aUniversity of California, San Francisco (UCSF) Department of Otolaryngology – Head and Neck Surgery, San Francisco, ^bUniversity of California, Irvine (UCI) Department of Otolaryngology, Irvine and ^cUniversity of California, Irvine (UCI) Department of Biomedical Engineering, Irvine, California, USA

Correspondence to Jeffrey D. Sharon, MD, Assistant Professor, Director of Balance and Falls Center, Division of Otolaryngology, Neurotology, and Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, 2380 Sutter St. 3rd Floor, San Francisco, CA 94115, USA. Tel: +415-514-8512; fax: +415-885-7546; e-mail: jeffrey.sharon@ucsf.edu

Curr Opin Neurol 2022, 35:84–89

DOI:10.1097/WCO.0000000000001024

KEY POINTS

- Migraine is involved in a wide variety of otologic symptoms, including tinnitus, hearing loss, vertigo, hyperacusis, otalgia, and ear pressure.
- Vestibular migraine is a common and disabling cause of vertigo.
- Otolaryngologists should be familiar with migraine, and always ask about a personal and family history of migraine when evaluating new patients.

by a physician but only 20% were diagnosed with vestibular migraine [11]. More women than men are affected, with a 3 to 1 ratio [12[■]]. At the senior author's (JDS) institution, a personal history of migraine is present 78% of the time, a family history of migraine in a first-degree family member is present 46% of the time, and a personal history of motion sickness is present 59% of the time (unpublished data).

Presentation

Diagnostic criteria are available from the Barany Society for both probable vestibular migraine and vestibular migraine, the latter of which has been added to the appendix of the International Criteria for Headache Disorders (ICHD-3) [13]. Patients with probable VM present with vestibular symptoms and have a history of migraine with or without aura or migrainous symptoms (photophobia, phonophobia, migraine headache) during attacks, whereas those with definite vestibular migraine, have both. However, a recent study showed that a large proportion of vertigo patients with migrainous features did not meet the ICHD criteria for vestibular migraine, most likely as a result of diagnostic criteria rather than intrinsic features unique to the vestibular migraine cohort [14].

Vestibular symptoms which are required for diagnosis include vertigo, postural imbalance, head motion-induced dizziness, and visually-induced vertigo. The most commonly associated vestibular symptom is spontaneous rotational vertigo, with an estimated prevalence of 67% [11]. In a cohort of 54 patients from the senior author's institution (unpublished data), the most common triggers for vertigo were motion (83%), stress (76%), busy visual scenes (72%), scrolling on a screen (67%), and impaired sleep (61%). In that cohort, 63% of patients experienced ear pressure with vestibular migraine attacks. Furthermore, patients with a history of vestibular migraine are at higher risk of cochlear disorders (tinnitus, sudden deafness, and

sensorineural hearing loss), with a nearly three-fold increase in likelihood [15]. Interestingly, about half of Meniere's patients, who suffer from tinnitus, hearing loss, and aural fullness also have a history of migraine, making it likely that Meniere's disease is in fact a migraine-related phenomenon [4,16].

Recently, vestibular migraine-PATHI (vestibular migraine Patient Assessment Tool and Handicap Inventory) was developed and validated as a disease specific outcome measure for vestibular migraine. Symptom specific measures, like the Dizziness Handicap Inventory (DHI), are certainly helpful in quantifying disease severity but may not capture the full spectrum of symptomatology. VM-PATHI was developed using a panel of experts, including audiologists, neurologists, and neurotologists, along with patient input. Over several iterations involving 95 patients, the item bank was refined and tested. The final questionnaire was found to have internal consistency (Cronbach's alpha 0.92), test-retest reliability, responsiveness, discriminative validity, and both face and content validity. It is freely available online at the UCSF Balance and Falls Center website (<https://ohns.ucsf.edu/balance-falls/>). Exploratory factor analysis uncovered six groupings within the items, covering the following themes: cognition, emotion, disequilibrium, headache equivalents, motion sensitivity, and anxiety. Of note, ear pressure had a mean score of 1.6 (0 = no problem, 1 = mild problem, 2 = moderate problem, 3 = severe severe problem, 4 = as bad as it can be), and clustered together with headache and head pressure.

Pathogenesis

The pathogenesis of vestibular migraine remains largely unknown, but there are several theories, related to sensory hypersensitivity, altered multi-sensory processing, and trigemino-vascular and calcitonin gene-related peptide (CGRP) effects on the vestibular system.

Migraine is believed to be caused by neuroinflammation of the trigemino-vascular system. The trigemino-vascular system is thought to be composed of peripheral trigeminal nerve endings innervating the pia, dura mater, and cranial blood vessels. The trigeminal nerve is responsible for pain sensation from the anterior two-thirds of the head, and it mediates pain signaling through the release of neuropeptides such as CGRP, substance P, neurokinin A, and nitrous oxide [17]. This process leads to vasodilation, mast cell degranulation, and neurogenic inflammation. CGRP, a neuropeptide involved in the efferent synapses of hair cell organs, such as the cochlea, semicircular canal, and the lateral line, has also been investigated in the pathogenesis of VM.

CGRP deletion in transgenic mice has been associated with reduced suprathreshold cochlear nerve activity and decreased vestibulo-ocular reflex (VOR) gain. CGRP deficient mice also show impaired otolith activity and decreased balance [18].

While a family history of migraine is common with vestibular migraine, not much is known about specific genetic alterations. An autosomal-dominant inheritance pattern has previously been described [11]. However, specific genetic loci have yet to be validated in vestibular migraine. Most recently, a mutation in the transient receptor potential (TRP) channel, a cation channel mediating pain, touch, hearing, and thermal sensation, has been associated with the development vestibular migraine in a single family [19].

Management

The management of vestibular migraine is similar to that of traditional migraine. Data are lacking regarding treatment effectiveness, and a 2015 Cochrane review found no high quality studies available for vestibular migraine [20]. Management involves conservative options, symptomatic and abortive treatment during acute attacks and prophylactic therapies. Nonmedical therapies include stress reduction, sleep hygiene, treatment of anxiety, avoiding dietary triggers, avoiding visual triggers, and stabilizing hormone fluctuations [21]. Acute vestibular migraine attacks can be treated with antiemetics to treat nausea and vestibular suppressants to treat the vestibular symptoms.

A variety of classical migraine prophylactics have been studied for the treatment of vestibular migraine. Multiple medication classes have shown efficacy in retrospective reviews including tricyclic antidepressants, mixed reuptake inhibitors, antiepileptics, beta-blockers, and calcium channel blockers [22]. The PROVEMIG trial, a recently completed placebo-controlled randomized controlled trial, investigated the efficacy of metoprolol in the treatment of vestibular migraine. There was no significant difference between the incidence of acute vertigo episodes between placebo and control groups. However, it is important to note that the trial was discontinued early due to poor patient accrual, but even so, the final analysis included 114 subjects, making it unlikely that there is a large, beneficial effect that was not observed [23].

Another promising treatment option for aborting an acute vestibular migraine attack is noninvasive vagus nerve stimulation. The noninvasive vagus nerve stimulator, a device in which a patient places electrodes on their neck that stimulate the vagus nerve, has recently been approved by the Food and

Drug Administration (FDA) for the treatment of episodic classical migraine. There is preliminary evidence that vagal nerve stimulation improves acute vertigo as well as headache during an acute attack in individuals with vestibular migraine [24].

OTHER AUDIOVESTIBULAR SYMPTOMS ASSOCIATED WITH MIGRAINE

Tinnitus and hyperacusis

Tinnitus may be associated with a migraine phenomenon, as both are similarly elusive in etiology but possibly share a pathophysiology linked by the central nervous system, specifically the activation of the trigeminal nerve and likely central hypersensitivity [25,26]. Tinnitus has been reported to be more prevalent in different types of migraine [27–29]. Pulsatile tinnitus is another symptom which can be seen in the context of migraine and may be resolved with migraine treatment with avoidance of dietary triggers with or without medication [30]. In a study examining the rate of tinnitus in patients with a definite diagnosis of migraine versus healthy subjects, 36.4% were found to have tinnitus while there were no patients with tinnitus among the healthy subjects ($P < 0.05$). Patients with migraine had over a three-fold increase in likelihood of having tinnitus [15]. Similarly, in a survey assessing cochleovestibular symptoms of migraine, 20% reported tinnitus [31]. This association has been found to be stronger in young individuals with migraine with aura [27]. The association of hyperacusis with chronic migraine is well described and is typically called “phonophobia” in the migraine literature. It is a symptom strongly associated with the severity of headache and has been shown to be improved from migraine prophylaxis therapy [32,33].

Cochlear migraine

While the relationship between migraine and vestibular symptoms has been assessed more carefully because formal diagnostic criteria were introduced in 2012, the relationship between migraine and cochlear symptoms is less recognized. Cochlear symptoms (e.g., fluctuating or sudden hearing loss) with or between headache attacks affect a smaller percentage of patients [31]. The concept of cochlear migraine was first described in 2018, with an aim to assess the relationship between migraine and auditory dysfunction. The major criteria for diagnosis include recurrent or fluctuating unilateral sensorineural hearing loss (low frequency or all frequencies) without vertigo or mild dizziness that does not

meet the criteria for vestibular migraine or migraine disorder along with aural fullness in the affected ear. Minor clinical features include aura before hearing loss; concurrent tinnitus; family history of migraine-related disorders; history of migraine or chronic headaches, or unilateral neck stiffness (ipsilateral to hearing loss); photophobia or phonophobia; motion sickness; visual motion intolerance; and sensitivity to atmospheric pressure changes [1,2]. Prior to this, research was performed to assess a correlation between migraine and otoacoustic emissions to carefully assess cochlear function. Despite normal hearing, patients with migraine have demonstrated lowering of otoacoustic emissions (TEAOEs) at various frequencies, along with central auditory dysfunction as evidenced by prolonged wave III latency and I-V IPL of auditory brainstem response [17]. Additional case reports have described patients with unilateral or bilateral, transient, and reversible mild hearing loss during a migraine attack [34].

Hearing loss

Subjective hearing change during vestibular migraine attacks is common as well, although it is unclear if that is a peripheral or perceptual process. A national database study revealed that migraine was independently associated with an increased likelihood of subjective tinnitus and hearing loss. This study of approximately 13,000 US adults demonstrated that migraineurs were more likely to have subjective hearing loss (25.0% vs. 16.6%, $P < 0.001$) and tinnitus (34.6% vs. 16.9%, $P < 0.001$) compared to the nonmigraineurs. Among migraineurs, a higher proportion of those with tinnitus also had hearing loss compared to those without tinnitus (40.0% vs. 15.3%, $P < 0.001$), and a higher proportion of those with hearing loss also had tinnitus compared to those without hearing loss (58.1% vs. 27.3%, $P < 0.001$) [35]. Additionally, a recent meta-analysis concluded that a history of migraine is a risk factor for sudden sensorineural hearing loss, with a pooled hazard ratio of 1.84 (95% confidence interval: 1.11–2.57; $P < .001$) [30]. Other large database analyses have also found that a history of migraine was 35–80% more likely in developing sudden hearing loss [36]. Finally, treatment of patients with sudden hearing loss using migraine prophylactic medications in addition to standard oral and intratympanic steroid has been found to improve lower frequency hearing [37^{***}]. A large portion of patients with chronic, sudden hearing loss (>3 months) have also been found to improve with migraine prophylactic therapy combined with intratympanic steroid injections [38].

Sinus pressure

The International Headache Society (IHS) has published criteria for headache that is attributed to rhinosinusitis. However, it is important to note that this entity is only in conjunction with an acute exacerbation of rhinosinusitis, and the IHS does not recognize chronic rhinosinusitis as a form of headache. It is common for patients with supposed chronic rhinosinusitis to have normal computed tomography findings or to fail standard antibiotic therapies. These patients often present with midfacial pain and pressure with rhinorrhea without evidence of infection or inflammation of the sinuses or nasal cavities. Many practitioners are now considering viewing this as a migraine variant instead of a manifestation of sinus or nasal pathology [8]. Patients with migraine are known to exhibit lacrimation, conjunctival injection, eyelid edema, or nasal congestion [39].

Many patients with “sinus” headache are now recognized to really have migraine. In a study of 100 people who believed they had sinus headache, 86% of participants met the definition of migraine with or without aura or probable migraine. A majority of patients in this study also presented with bilateral forehead and maxillary pain or pain in the distribution of the second division of the trigeminal nerve [7]. In addition to sinus pain, misdiagnosed patients often also present with sinus pressure and nasal congestion [40]. Overall, the literature supports that these patients respond to treatment with classical migraine medications, further supporting this entity as a form of migraine. A systematic review of the literature in 2013 shows that triptans are effective for the treatment of chronic facial pain without evidence of acute rhinosinusitis [41]. In 2007, a randomized, double-blind, placebo-controlled study assessing the efficacy of sumatriptan for patients with “sinus headache” found significant improvement in headache [42].

Aural fullness

Aural fullness (AF) is a symptom that can result from a number of different conditions, but most commonly presents with Eustachian tube dysfunction (ETD). Idiopathic aural fullness is the second most common classification after ETD. The relationship between AF and migraine is understudied. In a study assessing patients with aural fullness and migraine symptoms, 54% of patients with aural fullness met IHS criteria for migraine and all patients had symptomatic improvement with migraine prophylactics: verapamil (82%) or nortriptyline (18%). Migraine features that were commonly associated with aural fullness included

visual motion sensitivity (91%), head motion sensitivity (81%), sinus/facial pressure (72%), and phonophobia (72%) [43]. Another study showed that 74% of patients with migraine related aural fullness fulfilled a majority of the migraine headache criteria. Aural fullness in patients without ETD and normal imaging studies (no mass or third window) is most likely related to migraine [44].

Otalgia

Sensation to the ear is controlled by multiple nerves including afferents from the trigeminal nerve, which is implicated in migraine pathophysiology. Patients with classic migraine are more likely to report ear pain than patients with other types of headache and patients with otalgia are more likely to report headache than patients who do not have otalgia [45,46]. In a retrospective review of patients presenting with otalgia without another identifiable cause in a single otolaryngology practice, more than half had a prior history of headache and 65% met IHS criteria for migraine with or without aura. Otalgia was triggered by classical migraine triggers in the majority of patients. The majority of these patients had improvement in otalgia with classical migraine therapies [47]. Migraine patients with otalgia often present with other otologic symptoms including sinus pressure, aural pressure, or vertigo. Otalgia can also be seen as an otologic manifestation in patients with vestibular migraine.

CONCLUSION

Migraine is clearly involved in the generation of numerous otologic symptoms, including vertigo, tinnitus, aural pressure, otalgia, and hearing loss. A supplemental video abstract, <http://links.lww.com/CONR/A60> reviewing this is available for viewing. It seems likely to the authors that a clear understanding of how migraine affects the peripheral and central audiovestibular structures is required for an advancement in the conceptualization of otologic disease. Given its prevalence and myriad presentations, migraine should be on the differential diagnosis for almost any audiovestibular complaint.

Acknowledgements

None.

Financial support and sponsorship

Mehdi Abouzari, MD, PhD – supported by National Center for Research Resources and National Center for

Advancing Translational Sciences, National Institutes of Health (Grant TL1TR001415)

Conflicts of interest

1. Hamid R. Djalilian, MD – Equity in Cactus Medical, Elinava Technologies, Mindset Technologies, consultant to NXT Biomedical
2. Jeffrey D. Sharon, MD – consultant for Spiral Therapeutics, and research support from Eli Lilly and Advanced Bionics.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Lai J-T, Liu T-C. Proposal for a new diagnosis for cochlear migraine. *JAMA Otolaryngol Head Neck Surg* 2018; 144:185–186.
 2. Lin HW, Djalilian HR. The role of migraine in hearing and balance symptoms. *JAMA Otolaryngol Head Neck Surg* 2018; 144:717–718.
 3. Bruss D, Abouzari M, Sarna B, et al. Migraine features in patients with recurrent benign paroxysmal positional vertigo. *Otol Neurotol* 2021; 42:461–465.
 4. Sarna B, Abouzari M, Lin HW, Djalilian HR. A hypothetical proposal for association between migraine and Meniere's disease. *Med Hypotheses* 2020; 134:109430.
 5. Fenichel GM. Migraine as a cause of benign paroxysmal vertigo of childhood. *J Pediatr* 1967; 71:114–115.
 6. Uneri A. Migraine and benign paroxysmal positional vertigo: an outcome study of 476 patients. *Ear Nose Throat J* 2004; 83:814–815.
 7. Eross E, Dodick D, Eross M. The Sinus, Allergy and Migraine Study (SAMS). *Headache* 2007; 47:213–224.
 8. Godley FA, Casiano RR, Mehle M, et al. Update on the diagnostic considerations for neurogenic nasal and sinus symptoms: A current review suggests adding a possible diagnosis of migraine. *Am J Otolaryngol* 2019; 40:306–311.
 9. Dieterich M, Brandt T. Episodic vertigo related to migraine (90 cases): vestibular migraine? *J Neurol* 1999; 246:883–892.
 10. Formeister EJ, Rizk HG, Kohn MA, Sharon JD. The epidemiology of vestibular migraine: a population-based survey study. *Otol Neurotol* 2018; 39:1037–1044.
 11. Neuhauser HK, Radtke A, Brevern M von, et al. Migrainous vertigo: Prevalence and impact on quality of life. *Neurology* 2006; 67:1028–1033.
 12. Sharon JD, Krauter R, Kirk L, et al. Development and validation of VM-PATHI: ■ vestibular migraine patient assessment tool and handicap inventory. *Otology & Neurotology* 2020; 41:e494.
- This paper describes the development and validation of VM-PATHI, which is the first and only vestibular migraine specific patient reported outcome measure.
13. Lempert T, Olesen J, Furman J, et al. Vestibular migraine: diagnostic criteria. *J Vestib Res* 2012; 22:167–172.
 14. Abouzari M, Goshtasbi K, Moshtaghi O, et al. Association between vestibular migraine and migraine headache: yet to explore. *Otol Neurotol* 2020; 41:392–396.
 15. Hwang J-H, Tsai S-J, Liu T-C, et al. Association of tinnitus and other cochlear disorders with a history of migraines. *JAMA Otolaryngol Head Neck Surg* 2018; 144:712–717. doi:10.1001/jamaoto.2018.0939.
 16. Cawthorne T, Hewlett AB. Migraine and Ménière's disease. *Proc R Soc Med* 1962; 75:220–225.
 17. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. *Annu Rev Physiol* 2013; 75:365–391.
 18. Jones SM, Vijayakumar S, Dow SA, et al. Loss of (-)calcitonin gene-related peptide (cgrp) reduces otolith activation timing dynamics and impairs balance. *Front Mol Neurosci* 2018; 11:289.
 19. Frejo L, Giegling I, Teggi R, et al. Genetics of vestibular disorders: pathophysiological insights. *J Neurol* 2016; 263:S45–53.
 20. Maldonado Fernández M, Birdi JS, Irving GJ, et al. Pharmacological agents for the prevention of vestibular migraine. *Cochrane Database Syst Rev* 2015; 6:CD010600.
 21. Reploeg MD, Goebel JA. Migraine-associated dizziness: patient characteristics and management options. *Otol Neurotol* 2002; 23:364–371.
 22. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. *Headache* 2012; 52:930–945.

23. Bayer O, Adrion C, Al Tawil A, *et al.* Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). *Trials* 2019; 20:813.
24. Beh SC, Friedman DI. Acute vestibular migraine treatment with noninvasive vagus nerve stimulation. *Neurology* 2019; 93:e1715–e1719.
25. Vass Z, Steyger PS, Hordichok AJ, *et al.* Capsaicin stimulation of the cochlea and electric stimulation of the trigeminal ganglion mediate vascular permeability in cochlear and vertebro-basilar arteries: a potential cause of inner ear dysfunction in headache. *Neuroscience* 2001; 103:189–201.
26. Vass Z, Shore SE, Nuttall AL, Miller JM. Direct evidence of trigeminal innervation of the cochlear blood vessels. *Neuroscience* 1998; 84:559–567.
27. Guichard E, Montagni I, Tzourio C, Kurth T. Association between headaches and tinnitus in young adults: cross-sectional study. *Headache* 2016; 56:987–994.
28. Farri A, Enrico A, Lacilla M, Sartoris A. Tinnitus during headache: clinical-instrumental evaluation. *Acta Otorhinolaryngol Ital* 1999; 19:70–75.
29. Kirchmann M, Thomsen LL, Olesen J. Basilar-type migraine: clinical, epidemiologic, and genetic features. *Neurology* 2006; 66:880–886.
30. Weinreich HM, Carey JP. Prevalence of pulsatile tinnitus among patients with migraine. *Otol Neurotol* 2016; 37:244–247.
31. Bayazit Y, Yilmaz M, Mumbaç S, Kanlikama M. Assessment of migraine-related cochleovestibular symptoms. *Rev Laryngol Otol Rhinol (Bord)* 2001; 122:85–88.
32. Kelman L, Tanis D. The relationship between migraine pain and other associated symptoms. *Cephalalgia* 2006; 26:548–553.
33. Abouzari M, Tan D, Sarna B, *et al.* Efficacy of multi-modal migraine prophylaxis therapy on hyperacusis patients. *Ann Otol Rhinol Laryngol* 2020; 129:421–427.
34. Lee H, Whitman GT, Lim JG, *et al.* Hearing symptoms in migrainous infarction. *Arch Neurol* 2003; 60:113–116.
35. Goshtasbi K, Abouzari M, Risbud A, *et al.* Tinnitus and subjective hearing loss are more common in migraine: a cross-sectional NHANES Analysis. *Otol Neurotol* 2021; 42:1329–1333.
36. Chu C-H, Liu C-J, Fuh J-L, *et al.* Migraine is a risk factor for sudden sensorineural hearing loss: a nationwide population-based study. *Cephalalgia* 2013; 33:80–86.
37. Abouzari M, Goshtasbi K, Chua JT, *et al.* Adjuvant migraine medications in the treatment of sudden sensorineural hearing loss. *Laryngoscope* 2021; 131:E283–E288.
- This study retrospectively compared subjects with sudden sensorineural hearing loss. All were treated with standard of care oral and intratympanic steroids, but some also received migraine treatments (nortriptyline and topiramate). Hearing outcomes were better in the latter group. There was no significant difference between the incidence of acute vertigo episodes between placebo and control groups metoprolol-treated groups.
38. Goshtasbi K, Chua JT, Risbud A, *et al.* Treatment of long-term sudden sensorineural hearing loss as an otologic migraine phenomenon. *Otol Neurotol* 2021; 42:1001–1007.
39. Barbanti P, Fabbrini G, Pesare M, *et al.* Unilateral cranial autonomic symptoms in migraine. *Cephalalgia* 2002; 22:256–259.
40. Schreiber CP, Hutchinson S, Webster CJ, *et al.* Prevalence of migraine in patients with a history of self-reported or physician-diagnosed “sinus” headache. *Arch Intern Med* 2004; 164:1769–1772.
41. Patel ZM, Kennedy DW, Setzen M, *et al.* Sinus headache”: rhinogenic headache or miraine? An evidence-based guide to diagnosis and treatment. *Int Forum Allergy Rhinol* 2013; 3:221–230.
42. Ishkanian G, Blumenthal H, Webster CJ, *et al.* Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. *Clin Ther* 2007; 29:99–109.
43. Moshtaghi O, Ghavami Y, Mahboubi H, *et al.* Migraine-related aural fullness: a potential clinical entity. *Otolaryngol Head Neck Surg* 2019; 158:100–102.
44. Risbud A, Muhonen EG, Tsutsumi K, *et al.* Migraine features in patients with isolated aural fullness and proposal for a new diagnosis. *Otol Neurotol* 2021; 42:1580–1584.
- In this retrospective cohort study, subjects with aural fullness were studied. The investigators found that those with a history of migraine headaches per ICHD-3 criteria were quite similar to those without the same history, and that therefore many cases of isolated aural fullness may be caused by migraine.
45. Anttila P, Metsähonkala L, Mikkelsen M, *et al.* Comorbidity of other pains in schoolchildren with migraine or nonmigrainous headache. *J Pediatr* 2001; 138:176–180.
46. Kuttilla SJ, Kuttilla MH, Niemi PM, *et al.* Secondary otalgia in an adult population. *Arch Otolaryngol Head Neck Surg* 2001; 127:401–405.
47. Teixido M, Seymour P, Kung B, *et al.* Otagia associated with migraine. *Otol Neurotol* 2011; 32:322–325.